Global PharmaPartners
- Biotech or pharma, therapeutic R&D
Ampeptec has an exciting and robust development in the GLP-1 space with as an analogue of APT3712 which has the potential to be an oral, once a week treatment for obesity and diabetes, and (ii) a twice-a-month injection for obesity and type 2 diabetes, superior to Semaglutide and Tirzepatide, both of which are administered as once-weekly injections. APT3712 administered SQ has a much longer half-life than Semaglutide and Tirzepatide, and its anti-obesity activity is comparable to SQ Semaglutide. Therefore, APT3712 could be administered SQ less frequently than existing SQ anti-obesity drugs. Global annual sales of GLP-1 drugs projected to exceed $100 billion. APT3712 represents a major opportunity in a massive growing market.
Global PharmaPartners: FDF & API CDMO | Peptides | GLP-1 | Oncology | LAR Injectables | Specialty Pharma | Pharma/Biotech/Biosimilar | NDA's 505(b)(2)s | ANDA's | Out-licensing | Negotiations
Address
SpringfieldMissouri
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}